Nav: Home

Transplantation and cell therapy

March 29, 2016

Cellular Therapy is an emerging medical science that is today facing a unique developmental phase, well documented by the outstanding and growing numbers of clinical trials. Such an exponential growth requires proper infrastructures, cell repositories, clinical registries, technical and regulatory guidelines for appropriate cell manipulation and validation of the innovative therapeutic approaches in multicentric clinical trials.

The programme of the 5th Cell Therapy Day was designed in a joint effort by the EBMT Cellular Therapy and Immunobiology Working Party (CTIWP) and the local organising committee.

A panel of international speakers will discuss the following topics during the various sessions: "procedural aspects of minimally-manipulated cell products"; "quality control"; "impact of JACIE in Europe and beyond"; "from Cell Therapy facilities to GMP"; "highlights on new applications" (including the development of CD19-CAR T cells).

The following day, on Tuesday 5 April, the CTIWP will hold its scientific session. New scientific insights will be presented and debated, including the presentation of the prestigious Jon J. van Rood Award for the best paper in the immunobiology of allogeneic haematopoietic stem cell transplantation.

The EBMT Cell Therapy Day and the scientific sessions have become an integral part of the CTIWP's mission. The CTIWP aims at fostering cellular therapy in Europe, through a continuous crosstalk between basic science findings, transplant immunobiology observations and implementation of industry sponsored-trials cellular designed to answer unmet medical needs. Christian Chabannon, Secretary of the CTIWP explains: "The Cellular Therapy and Immunobiology Working Party is taking advantage of the culture and background of the EBMT at this exciting time when we see innovative cellular and gene therapies enter the field concomitantly with a renewed interest of the industry for the field."

In addition, one of the objectives of the CTIWP is to identify centres of excellence that have the additional capacity to design and evaluate innovative cellular therapies on their own. The following example illustrates well this objective: Chiara Bonini, Head of the Experimental Hematology Unit in San Raffaele Scientific Institute in Milan and Chair of the EBMT CTIWP, launched an outstanding procedure called "TCR-gene editing" allowing to generate a large number of T lymphocytes specific for a given tumor. The results of this innovative technology were published in 2012 in the Nature Medicine journal. Since then, this procedure has been implemented by many transplant research centres around the world. One of them is the Hospital Clinic de Barcelona (HCB) that is currently implementing a platform of development of CAR-CD19 and will launch a clinical trial using this CAR-CD19 in adults and children.
For further information about the various oral and poster sessions, please visit the Annual Meeting website - and the online programme:

About the European society for Blood and Marrow Transplantation (EBMT)

The EBMT is a not-for-profit medical and scientific organisation established in 1974. It is dedicated to fighting life-threatening blood cancers and diseases and improving patients' lives. The EBMT Members - more than 4,000 physicians, nurses, scientists and other healthcare professionals - participate in a unique collaborative network of peers involved in haematopoietic stem cell transplantation (HSCT) and cellular therapy research. The membership encompasses at least 600 centres who are performing or are involved in HSCT in more than 60 countries. The EBMT holds a central role in performing co-operative studies and disseminating state-of-the-art knowledge aimed at increasing survival rates and enhancing the quality of life of patients with life-threatening blood cancers and diseases.

For further information about the EBMT, please visit the website: and follow us on Twitter: @TheEBMT

About the EBMT Cellular Therapy and Immunobiology Working Party (CTIWP)

The mission of the EBMT CTIWP is to understand and exploit the biological including immunological events occurring upon haematopoietic stem cell transplantation at large, and to implement modern cellular therapies based on cell and gene engineering approaches to improve transplantation outcomes.
  • Expand the existing EBMT Registry through the capture of detailed data that describe the nature of cellular therapies - minimally manipulated as well as extensively manufactured delivered to recipients, whatever the provider: cell processing facility or industry
  • Further our understanding of biological mechanisms underlying the clinical efficacy and toxicity of HSCT and hematopoietic cellular therapies
  • Promote exchanges and cooperation between centers and programs engaged in the development of innovative cellular therapies that belong to the same family of products (genetically engineered T-cells, NK cells, MSC ...)
  • Define the minimal requirements to participate in early industry-sponsored clinical trials that will evaluate this new generation of cellular products manufactured and distributed as Advanced Therapy Medicinal Products, and map European centers and programs enabled with such capacities.

European Society for Blood and Marrow Transplantation

Related Clinical Trials Articles:

Giving children a voice in clinical trials
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.
Better health for women involved in clinical trials
Women who participate in obstetric and gynecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London.
Final artificial pancreas clinical trials now open
Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.
Why the bar needs to be raised for human clinical trials
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
New drug formulary will help expedite use of agents in clinical trials
The National Cancer Institute (NCI) today launched a new drug formulary (the 'NCI Formulary') that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
Review examines diversity in dermatology clinical trials
Racial and ethnic groups can be underrepresented in medical research.
Reshaping the future of global clinical trials practice
Researchers at the University of Liverpool have developed a new international guideline to help standardize how results from clinical trial studies are reported.
Fewer cardiovascular drugs being studied in clinical trials
The number of cardiovascular drugs in the research pipeline has declined across all phases of development in the last 20 years even as cardiovascular disease has become the No.
Sex hormones skew outcomes in clinical trials -- here's how
Clinical research often excludes females from their trials under the assumption that 'one size fits all,' that a painkiller or antidepressant will be equally effective in subjects of either sex, but a growing number of scientists are criticizing this approach.
Nearly half of pediatric clinical trials go unfinished or unpublished
Clinical trials in children commonly go either uncompleted or unpublished, finds a comprehensive study conducted by researchers at Boston Children's Hospital.

Related Clinical Trials Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...